Gillette P, Garson A, Eterovic E, Neches W, Mullins C, McNamara D G
J Pediatr. 1978 Jan;92(1):141-4. doi: 10.1016/s0022-3476(78)80096-1.
To determine the effectiveness of oral propranolol in children, we administered 0.5 to 4.0 mg/kg/day of the drug to 64 children (age one day to 20 years); 41 with cardiac dysrhythmias, six with isiopathic hypertrophic subaortic stenosis, and 17 with paroxysmal hypoxemic spells associated with right ventricular infundibular obstruction. A new liquid form of propranolol (10 mg/ml) was administered to 37 of the younger patients, and tablets were given to the other 27. Propranolol improved the dysrhythmia in 31 of 41 patients, being notably effective in supraventricular tachycardia and ventricular tachycardia associated with a prolonged QT interval. The drug also eliminated symptoms attributed to IHSS in six of six patients and abolished hypoxemic spells in 12 of 17. The liquid and tablets were equally effective; and the liquid had the advantage of allowing for accurate dose changes in younger children. We conclude that oral propranolol is an excellent drug for use in pediatric patients with certain types of cardiac disease.
为确定口服普萘洛尔对儿童的疗效，我们给64名儿童（年龄从1天至20岁）服用了0.5至4.0毫克/千克/天的该药物；其中41名患有心律失常，6名患有特发性肥厚性主动脉瓣下狭窄，17名患有与右心室漏斗部梗阻相关的阵发性低氧血症发作。37名较年幼的患者服用了新的液体剂型普萘洛尔（10毫克/毫升），另外27名患者服用了片剂。普萘洛尔使41名患者中的31名心律失常得到改善，对室上性心动过速和伴有QT间期延长的室性心动过速尤为有效。该药物还消除了6名患者中由特发性肥厚性主动脉瓣下狭窄引起的症状，并消除了17名患者中12名的低氧血症发作。液体剂型和片剂同样有效；液体剂型的优点是能让年幼儿童准确调整剂量。我们得出结论，口服普萘洛尔是用于患有某些类型心脏病的儿科患者的一种极好的药物。
